Biovica International AB (publ) EBIT

Biovica International AB (publ) (BIOVIC-B.ST) currently reports a EBIT of $-71M as of July 2026. That compares with $-82M in the prior-year period — up 12.9% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Biovica International AB (publ)'s EBIT history and peer comparisons.

Biovica International AB (publ)'s EBIT increased from $-82M to $-71M — a 12.9% year-over-year increase (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biovica International AB (publ)'s EBIT of $-71M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Biovica International AB (publ) reported $-71M in EBIT as of July 2026. That compares with $-82M in the prior-year period — up 12.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-71M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Biovica International AB (publ), and consider following BIOVIC-B.ST for alerts when major investors trade the stock.